c-Myc overcomes cell cycle inhibition by CBFβ-SMMHC, a myeloid leukemia oncoprotein

Cancer Biology and Therapy

Volumn 1, Issue 5, 2002, Pages 492-496

  Bernardin, Florence ^a   Yang, Yandan ^a   Civin, Curt I ^a   Friedman, Alan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AML1; c Myc; CBF; CBF SMMHC; RUNX1

Indexed keywords

4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; DNA BINDING PROTEIN; DRUG DERIVATIVE; ESTROGEN RECEPTOR; INV(16) FUSION PROTEIN, HUMAN; MYC PROTEIN; MYOSIN; MYOSIN HEAVY CHAIN; ONCOPROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; ZINC;

ANIMAL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; DRUG ANTAGONISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MYELOID LEUKEMIA; PHYSIOLOGY;

ANIMALS; CELL CYCLE; CELL LINE; DNA-BINDING PROTEINS; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOID; MICE; MYOSIN HEAVY CHAINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; S PHASE; SMOOTH MUSCLE MYOSINS; TAMOXIFEN; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS; ZINC;

EID: 1842837177     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.1.5.163     Document Type: Article

References (27)

1. Friedman AD. Leukemogenesis by CBF oncoproteins. Leukemia 1999; 13:1932-42.
2. Liu PP, Seidel N, Bodine D, Speck NA, Tarle S, Collins FS. Acute myeloid leukemia with inv(16) produces a chimeric transcription factor with a myosin heavy chain tail. CSH Symp Quant Biol 1994; 59:547-53.
3. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, et al. CBFβ-SMMHC, expressed in M4eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene 1997; 15:1315-27. (Pubitemid 27429748)
4. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD. The core binding factor α interaction domain and the smooth muscle myosin heavy chain segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem 1998; 47:31534-40. (Pubitemid 28533176)
5. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher III FJ, Friedman, AD. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF-a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 2000; 19:2695-703. (Pubitemid 30326419)
6. Castilla HL, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia. Nature Genet 1999; 23:144-6. (Pubitemid 29455384)
7. Yang Y, Wang W, Cleaves R, Zahurak M, Cheng L, Civin CI, et al. Acceleration of G1 cooperates with CBFβ-SMMHC to induce acute leukemia in mice. Cancer Res 2002; 62:2232-5.
8. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, et al. Expression of the AML-1 oncogene shortens the G1 phase of the cell cycle. J Biol Chem 2000; 275:3438-45. (Pubitemid 30083051)
9. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 2001; 21:5577-90. (Pubitemid 32702461)
10. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001; 21:6470-83. (Pubitemid 32927415)
11. Rothberg PG, Erisman MD, Diehl RE, Rovigatti UG, Astrin SM. Structure and expression of the oncogene c-myc in fresh tumor material from patients with hematopoietic malignancies. Mol Cell Biol 1984; 4:1096-103. (Pubitemid 14050726)
12. Calabretta B, Venturelli D, Kaczmarek L, Narni F, Talpaz M, Anderson B et al. Altered expression of G1-specific genes in human malignant cells. Proc Natl Acad Sci USA 1986; 83:1495-8. (Pubitemid 16016156)
13. Preisler HD, Sato H, Yang PM, Wilson M, Kaufman C, Watt R. Assessment of c-myc expression in individual leukemic cells. Leuk Res 1988; 12:507-16.
14. Evinger-Hodges MJ, Bresser J, Brouwer R, Cox I, Spitzer G, Dicke K. Myc and sis expression in acute myelogenous leukemia. Leukemia 1988; 2:45-9. (Pubitemid 18052824)
15. Li Y-S. Double minutes in acute myeloid leukemia. Int J Cancer 1983; 32:455-9.
16. Bruckert P, Kappler R, Scherthahn H, Link H, Hagmann F, Zankl H. Double minutes and c-myc amplification in acute myelogenous leukemia: are they prognostic factors? Cancer Genet Cytogenet 2000; 120:73-9.
17. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, and Morra E. C-kit mutations in core binding factor leukemias. Blood 2000; 95:726-7. (Pubitemid 30041697)
18. Preisler HD, Raza A, Larson R, LeBeau M, Browman G, Goldberg J et al. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: a leukemia intergroup pilot study. Blood 1989; 73:255-62. (Pubitemid 19040985)
19. Palacois R and Steinmetz M. IL-3 dependent mouse clones that express B220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes. Cell 1985; 41:727-34. (Pubitemid 15225429)
20. Eilers M, Picard D, Yamamoto KR, Bishop JM. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 1989; 340:66-8. (Pubitemid 19172604)
21. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evans GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucl Acids Res 1995; 23:1686-90.
22. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19:1-11.
23. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid proto-oncogenes AML1 and PEBP2β/CBFβ, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 1994; 14:5558-68. (Pubitemid 24235984)
24. Britos-Bray M, Ramirez M, Cao W, Wang X, Liu PP, Civin CI, et al. CBFβ-SMMHC, expressed in M4eo AML, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 1998; 92:4344-52. (Pubitemid 28544352)
25. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000; 20:3497-509. (Pubitemid 30243895)
26. Herman JG, Jen J, Merlo A, Baylin SB. Hyper-methylation-associated inactivation indicates a tumor suppressor role for p15(INK4B1). Cancer Res 1996; 56:722-7.
27. Eischen CM, Roussel FM, Korsmeyer SJ, Cleveland JL. Bax loss impairs myc-induced apoptosis and circumvents the selection of p53 mutations during myc-mediated lymphomagenesis. Mol Cell Biol 2001; 21:7653-62. (Pubitemid 32988776)